CeraVe describes its Acne Control Gel as a 2% salicylic-acid treatment that “clears acne and helps prevent new breakouts from forming.”
Those two promises sit next to each other on the product page. But they do not ask quite the same question of the evidence. Treating acne that is already there is one outcome. Showing that new breakouts are prevented is another.
What does the evidence show?
FG did not identify any eligible public clinical outcome evidence showing that the current U.S. CeraVe Acne Control Gel prevents new breakouts.
That does not mean the gel cannot help prevent new breakouts. It means FG did not find eligible public clinical evidence demonstrating that outcome for this finished product.
Has this exact CeraVe gel been clinically studied?
FG did not verify any publicly accessible clinical report or study that clearly identified the exact current U.S. CeraVe Acne Control Gel, or a formulation shown to be unambiguously identical to it.
That distinction matters because studies involving salicylic acid are not automatically studies of CeraVe Acne Control Gel.
Free weekly newsletter
Get every new investigation directly in your inbox.
Science Checks and Brand Checks across the anti-ageing industry — delivered free.
One 2025 study, for example, examined an unnamed gel containing salicylic acid. The available record did not establish that it was CeraVe, a L’Oréal product, the current U.S. formulation, or an identical formula.
So it cannot serve as direct evidence for this product.
What does the evidence for 2% salicylic acid show?
The strongest applicable evidence FG verified came from a placebo-controlled study of people with mild-to-moderate acne.
It tested a 2% salicylic-acid lotion delivered on pads and used twice daily. The study reported significant reductions in acne lesion counts compared with placebo at several points over 12 weeks.
That provides limited indirect evidence that 2% topical salicylic acid can improve existing acne.
But the study did not test CeraVe Acne Control Gel. Its pad-and-lotion formulation was different from the current leave-on CeraVe gel, so its results cannot establish how the finished CeraVe product performs.
It also measured improvement in lesions, not complete or near-complete clearance.
Why doesn’t reducing acne lesions prove that new breakouts are prevented?
Because they are different outcomes.
A study can measure whether acne that is already present improves. But showing prevention requires a different kind of measurement: whether new lesions appear, whether acne returns after improvement, or whether clearance is maintained.
FG did not verify those outcomes in the relevant 2% salicylic-acid studies.
So evidence that an acne treatment reduced existing lesions cannot, on its own, show that it prevented new ones from forming.
What does the product label establish?
The current Drug Facts record states that CeraVe Acne Control Gel is a leave-on topical acne treatment containing 2% salicylic acid. Its directions call for applying a thin layer over the affected area, starting once daily and increasing to as often as three times daily if needed and tolerated.
The official product page and current label also link the gel with both acne-clearing and prevention language.
Those records establish what the product is and what is claimed for it. They do not independently establish its clinical performance.
Salicylic acid’s place in the OTC acne-treatment framework, and the availability of clearing- or prevention-style labeling language in that regulatory context, should not be treated as product-specific clinical proof.
So, does CeraVe Acne Control Gel prevent new breakouts?
CeraVe says it helps do so. But FG did not find eligible public clinical evidence demonstrating that outcome for the current gel.
The evidence FG verified tells us something about treating acne that already exists. It does not answer the separate question of whether this product prevents the next breakout.
